


Supplementary Data


Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers

Donna M. Barten*, Gregory W. Cadelina, Nina Hoque, Lynn B. DeCarr, Valerie L. Guss, Ling Yang, Sethu Sankaranarayanan, Paul D. Wes, Marianne E. Flynn, Jere E. Meredith, Michael K. Ahljianian and Charles F. Albright
Neuroscience Drug Discovery, Bristol-Myers Squibb, Wallingford, CT, USA

Accepted 23 February 2011




Supplementary Fig. 1. Soluble brain h-tau in Tg4510 mice is similar when measured using the Invitrogen, HT-7BT2 and full length Tau12-DC39 assays.



Supplementary Fig. 2. CSF h-tau measurements in transgenic mice. A) Correlation between Invitrogen and Innotech ELISA assays in Tg4510 CSF. B) CSF h-tau in 3xTg mice increases with age using the HT7-BT2 assay. ** $p < 0.01$ compared to 2.2 month mice.

*Correspondence to: Dr. Donna M. Barten, Neuroscience Drug Discovery, Bristol-Myers Squibb, 3CD-405, PO Box 5100, Wallingford, CT 06492, USA. Tel.: +1 203 677 6962; Fax: +1 203 677 7569; E-mail: donna.barten@bms.com.



Supplementary Fig. 3. Doxycycline treatment for 6 weeks reduced CSF h-tau measured in three different assays.